Loading clinical trials...
Loading clinical trials...
Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)
Conditions
Interventions
Cetuximab
FOLFIRI
Locations
4
Germany
Universitätsklinikum Knappschaftskrankenhaus
Bochum, Germany
Onkologisches Zentrum (Dachau II)
Dachau, Germany
Kliniken-Essen-Mitte Evang. Huyssens-Stiftung
Essen, Germany
Evangelisches Krankenhaus Hamm
Hamm, Germany
Start Date
December 29, 2020
Primary Completion Date
June 11, 2024
Completion Date
June 11, 2024
Last Updated
June 8, 2025
NCT04624555
NCT05080673
NCT04668872
NCT07129512
NCT02232152
NCT03693846
Lead Sponsor
TheraOp
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions